Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Immunotherapy in Advanced Small Bowel and Colorectal Cancers
NCT04491955Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2020
- Primary completion
- Oct 2022
- Modality
- Prophylactic Vaccines, Immune Checkpoint Inhibitors, Immunomodulatory ADCs
- Countries
- 1
01
Overview
A Phase 2 trial of CV301, bintrafusp alfa, nogapendekin alfa inbakicept, NHS-IL-12 in small bowel cancer, colorectal cancer (CRC), sponsored by National Cancer Institute. Started Sep 2020; status: completed.
02
Drugs
CV301bintrafusp alfanogapendekin alfa inbakiceptNHS-IL-12
03
Conditions
small bowel cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04491955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04491955.